- Home
- LEXX vs BOLT Comparison
LEXX vs BOLT Comparison
Compare LEXX & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- BOLT
- Stock Information
- Founded
- LEXX 2004
- BOLT 2015
- Country
- LEXX Canada
- BOLT United States
- Employees
- LEXX N/A
- BOLT N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- BOLT Health Care
- Exchange
- LEXX Nasdaq
- BOLT Nasdaq
- Market Cap
- LEXX 19.6M
- BOLT 16.8M
- IPO Year
- LEXX N/A
- BOLT 2021
- Fundamental
- Price
- LEXX $0.83
- BOLT $5.71
- Analyst Decision
- LEXX Strong Buy
- BOLT Buy
- Analyst Count
- LEXX 1
- BOLT 3
- Target Price
- LEXX $7.00
- BOLT $50.00
- AVG Volume (30 Days)
- LEXX 146.6K
- BOLT 24.1K
- Earning Date
- LEXX 07-11-2025
- BOLT 08-12-2025
- Dividend Yield
- LEXX N/A
- BOLT N/A
- EPS Growth
- LEXX N/A
- BOLT N/A
- EPS
- LEXX N/A
- BOLT N/A
- Revenue
- LEXX $525,923.00
- BOLT $3,638,000.00
- Revenue This Year
- LEXX $0.62
- BOLT N/A
- Revenue Next Year
- LEXX $14.19
- BOLT $24.14
- P/E Ratio
- LEXX N/A
- BOLT N/A
- Revenue Growth
- LEXX 29.95
- BOLT N/A
- 52 Week Low
- LEXX $0.82
- BOLT $5.20
- 52 Week High
- LEXX $4.38
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- LEXX 31.77
- BOLT 42.69
- Support Level
- LEXX $0.93
- BOLT $5.36
- Resistance Level
- LEXX $1.05
- BOLT $6.07
- Average True Range (ATR)
- LEXX 0.07
- BOLT 0.44
- MACD
- LEXX -0.00
- BOLT -0.01
- Stochastic Oscillator
- LEXX 14.14
- BOLT 25.58
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.